GRAIL (GRAL) said Monday the first patient has been tested for eligibility with the company's investigational lung cancer ctDNA blood-based test in a phase 3 trial assessing adjuvant treatment regimens in people with non-small cell lung cancer.

The trial, which is sponsored by AstraZeneca (AZN) in collaboration with Daiichi Sankyo, uses GRAIL's targeted methylation platform to detect ctDNA, GRAIL said.

People will be screened with the GRAIL assay before surgery to assess eligibility for post-surgery randomization to an adjuvant treatment regimen, the company said.

Price: 15.53, Change: -0.39, Percent Change: -2.45